Subscribe: Market Wire - Pharmaceuticals and Biotech: Drugs
http://img.marketwire.com/rss/mwPBDR.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
announced  announces  cannabis  company  jul  july  marketwired jul  marketwired july  marketwired  medical  nasdaq  otc pink  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Drugs

Marketwired - Drugs



Marketwired - Drugs



Last Build Date: Thu, 27 Jul 2017 13:19:20 EDT

Copyright: Copyright: (C) Marketwired
 



ViaDerma, Inc. Starts Phase II of MMJ and Recreational Testing in Canada, also is Now Fast Tracking its Topical Antibiotic with the BFAD (Bureau of Food and Drugs) in Philippines for Approval of its FDA Registered Product

Thu, 27 Jul 2017 12:48:27 EDT

ViaDerma and its Partners in the Philippines Have Had Quick Initial Results and Look to Expand Initial Test Studies and have Partnered with Major Hospitals and Its Main Distributor in a Move to Fast track its FDA Registered Topical Antibiotic




Neptune reçoit un avis de NASDAQ concernant l'exigence relative au cours acheteur minimum

Thu, 27 Jul 2017 09:23:41 EDT

LAVAL, QUÉBEC--(Marketwired - 27 juillet 2017) - Neptune Technologies & Bioressources inc. (« Neptune » ou la « Société ») (NASDAQ:NEPT)(TSX:NEPT) a annoncé qu'elle a reçu, le 21 juillet 2017, un avis du service d'admissibilité à la cote de NASDAQ pour ne pas avoir maintenu un cours acheteur d'au moins 1,00 $ US par action dans les 30 derniers jours ouvrables, comme l'exige la règle d'inscription à la cote 5550(a)(2) de NASDAQ sur le cours acheteur.




Neptune Receives Nasdaq Notification Regarding Minimum Bid Requirements

Thu, 27 Jul 2017 09:23:10 EDT

LAVAL, QUÉBEC--(Marketwired - July 27, 2017) - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ:NEPT)(TSX:NEPT), announces that on July 21, 2017 it received notification from Nasdaq Listing Qualifications Department for failing to maintain a minimum bid price of US$1.00 per share for the last 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2) - bid price.




Diabetes: Silence the Messenger, Don't Shoot It -- SECFilings.com

Thu, 27 Jul 2017 09:15:00 EDT

REDONDO BEACH, CA--(Marketwired - Jul 27, 2017) - SECFilings.com, a leading financial news and information portal offering free real-time public company filing alerts, announces the publication of an article discussing PreveCeutical Medical Inc. (CNSX: PREV) and its ground breaking research targeting a gene therapy for Type 2 diabetes and obesity through silencing of the protein, PTP-1B.




Leading Manufacturer of Pharmaceutical Grade Probiotics Educates Consumers About Probiotic Powder for Improving Skin Health

Thu, 27 Jul 2017 09:04:00 EDT

Natren Probiotics Shares Tips and Tricks on Facebook Live to Teach People Ways to Care for Skin Issues Using Probiotics




Synthego Announces World's First Modified Synthetic sgRNA Libraries for Arrayed Whole Genome CRISPR Screening

Thu, 27 Jul 2017 09:02:00 EDT

Offers greater accuracy and comprehensive target identification in all human cell types




Mount Tam Biotechnologies Announces Collaboration to Study Potential in Parkinson's Disease

Thu, 27 Jul 2017 09:00:00 EDT

NOVATO, CA--(Marketwired - Jul 27, 2017) - Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR modulators, is pleased to announce that it has entered into an Agreement with the University of Chile and the Laboratory of Claudio Hetz, Ph.D., to explore the potential of Mount Tam's novel compounds in Parkinson's disease. Under this Agreement, Dr. Hetz and his colleagues will use their extensive experience and capabilities in testing investigational drug candidates in animal models of neurodegenerative diseases to better understand the potential for selective mTORC1 inhibitors in Parkinson's Disease.




Propanc Biopharma Provides Shareholder Update on R&D Activities for PRP

Thu, 27 Jul 2017 08:30:00 EDT

Company prepares for Clinical Trial Application to be filed in the UK




Golden Leaf CEO William Simpson Issues Letter to Shareholders

Thu, 27 Jul 2017 08:00:00 EDT

TORONTO, ON--(Marketwired - July 27, 2017) - Golden Leaf Holdings Ltd. ("GLH" or the "Company") (CSE: GLH) (OTCQB: GLDFF), a leading cannabis oil solutions company built around recognized brands, is issuing the letter below to shareholders.

To Our Valued Shareholders:




Moleculin Strengthens Board of Directors with Appointment of John M. Climaco

Thu, 27 Jul 2017 07:30:00 EDT

HOUSTON, TX--(Marketwired - July 27, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced the appointment of John M. Climaco as an independent member of the Company's Board of Directors, effective July 24, 2017 to fill a board vacancy.




Marijuana Company of America Completes $250,000 Investment in MoneyTrac Technology

Thu, 27 Jul 2017 07:30:00 EDT

ESCONDIDO, CA--(Marketwired - Jul 27, 2017) - MARIJUANA COMPANY OF AMERICA, INC. ("MCOA" or the "Company") (OTC PINK: MCOA), an innovative cannabis and hemp corporation, is pleased to announce that it has completed an investment of $250,000 into MoneyTrac Technology, Inc. ("MTT"), a subsidiary of Global Payout, Inc. (OTC PINK: GOHE), in exchange for a 15% ownership interest.




Medical Devices: Reviewing Regulatory Changes in the US and EU, New Webinar Hosted by Xtalks

Thu, 27 Jul 2017 07:30:00 EDT

In the United States, MDUFA and other regulations updated in 2017, have an immediate impact on how medical device manufacturers are developing and marketing their products; There are steps medical device manufacturers can take to comply with all regulations and help ensure successful clinical trial execution




Newstrike Gains Access to Unparalleled Insight and Proven Branding Expertise with Recent Appointments to Advisory Board

Thu, 27 Jul 2017 07:00:00 EDT

Recent Appointees bring proven expertise key to successfully launching brands in evolving market




Angle PLC: Preliminary Results

Thu, 27 Jul 2017 02:43:24 EDT

GUILDFORD, UNITED KINGDOM--(Marketwired - Jul 27, 2017) - ANGLE PLC (AIM: AGL) (OTCQX: ANPCY)




Tetra Bio-Pharma CSO Discusses Opportunities in Exclusive CFN Media Interview

Wed, 26 Jul 2017 14:33:18 EDT

SEATTLE, WA--(Marketwired - Jul 26, 2017) -  CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article and exclusive interview covering Tetra Bio-Pharma Inc. (CSE: TBP) (CSE: TBP.CN) (CNSX: TBP) (OTCQB: TBPMF). The interview, with Chief Science Officer Dr. Guy Chamberland, and article discuss the company's progress in advancing its clinical pipeline designed to bring innovative cannabis products to market. With a new CEO and new partnerships, these efforts could be accelerated over the coming quarters as the company gears up for pivotal Phase III clinical trials demonstrating the benefits of inhaled cannabis.




Marijuana Company of America Issues Correction to Previous Announcement on the Full Patent for Its HempSMART Brain CBD Product

Wed, 26 Jul 2017 14:06:24 EDT

ESCONDIDO, CA--(Marketwired - Jul 26, 2017) - MARIJUANA COMPANY OF AMERICA ("MCOA" or the "Company") (OTC PINK: MCOA), an innovative cannabis and hemp corporation, issues a correction to its previous announcement, "Marijuana Company of America Files for Non-Provisional Patent Protection on Its HempSMARTT Brain CBD Product" issued at 7:30 am Eastern Time today.




NutraGlow Introduces New Super B Sublingual Vitamin Supplement for Improved Energy, Metabolism and Brain Function

Wed, 26 Jul 2017 09:18:00 EDT

Super B Sublingual Vitamin Supplement Offers Superior Absorption Rates and Effectiveness Versus Pill-Form Alternatives




Top 4 Companies Reinventing Cannabinoid Delivery -- CFN Media

Wed, 26 Jul 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Jul 26, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing the need for improved delivery technologies for cannabinoid-based therapies and four companies that are on the cutting edge with innovative systems. Cure Pharmaceutical Corp. (OTCQB: CURR) has an oral thin film; AXIM® Biotechnologies Inc. (OTCQB: AXIM) is employing chewing gum in its clinical programs; Lexaria Corp. (OTCQB: LXRP) has developed a lipid encapsulation technology; and PreveCeutical Medical Inc. (CNSX: PREV) is working with a Sol-Gel nasal delivery system.




NetworkNewsWire Announces Publication on Leading Innovators Working to Unlock a Treatment for Alzheimer's

Wed, 26 Jul 2017 08:30:00 EDT

NEW YORK, NY--(Marketwired - Jul 26, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring India Globalization Capital, Inc. (NYSE MKT: IGC), a client of NNW positioned as a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.




BioVie Files Patent Application in Japan for BIV201 for the Treatment of Ascites Due to Liver Cirrhosis

Wed, 26 Jul 2017 08:00:00 EDT

BEVERLY, MA--(Marketwired - July 26, 2017) - BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, announced today the filing of an application in Japan for patent coverage of the Company's new drug candidate BIV201 for the treatment of ascites in patients with advanced liver cirrhosis. This follows the recent issuance of US Patent No. 9,655,945 for the use of BIV201 to treat this medical condition. The Company is pursuing an approach known as the "patent prosecution highway" in order to seek an expedited patent approval in Japan, which may take less than one year.




Marijuana Company of America Files for Non-Provisional Patent Protection on Its HempSmart Brain CBD Product

Wed, 26 Jul 2017 07:30:00 EDT

ESCONDIDO, CA--(Marketwired - Jul 26, 2017) - MARIJUANA COMPANY OF AMERICA ("MCOA" or the "Company") (OTC PINK: MCOA), an innovative cannabis and hemp corporation, is pleased to announce that its wholly owned subsidiary, H Smart, Inc., has successfully filed for a full non-provisional patent with the U.S. Patent and Trademark Office, Appl. No. 87/531,833, for its proprietary Cannabidiol (CBD) formulation hempSMARTT Brain.




Liberty Health Sciences Commences Trading on the CSE Following Closing of Business Combination

Wed, 26 Jul 2017 07:00:00 EDT

TORONTO, ONTARIO--(Marketwired - July 26, 2017) -




HempLife Today acquires additional space in order to better fulfill and expand its shipping of Free-Trial offer

Wed, 26 Jul 2017 07:00:00 EDT

DENVER, CO--(Marketwired - Jul 26, 2017) -  Ubiquitech Software Corp. (OTC PINK: UBQU), through its subsidiary HempLife TodayT, an innovative and growing Company offering the finest CBD (Cannabidiol) products derived from Hemp, is announcing it has acquired additional warehouse/office space in order to better serve its successful Free-Trial offer of CannazALLT CBD GelCaps.




Top Pharma Companies Now Include Communicating HEOR Data as a Part of Their Medical Affairs Strategy

Tue, 25 Jul 2017 17:42:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwired - July 25, 2017) - New analysis of Top 10, Top 50 and small medical device companies revealed that health economics and outcomes research (HEOR) data is increasingly becoming a part of surveyed medical affairs teams' strategies, according to pharmaceutical business intelligence firm Cutting Edge Information.




Tetra Bio-Pharma Announces Stock Option Grant to CEO

Tue, 25 Jul 2017 17:00:00 EDT

OTTAWA, ONTARIO--(Marketwired - July 25, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announces that it has made a grant of stock options under its stock option plan to the newly appointed Chief Executive Officer, Bernard Fortier to acquire a total of 400,000 common shares of the Company. All of the options are exercisable at a price of $0.80 per share. All of the options will vest immediately of the date of grant. The options have a term of 4 years and are subject in all respects to the terms of Tetra's stock option plan.




Neptune publiera ses résultats du premier trimestre pour la période de trois mois se terminant le 30 juin 2017

Tue, 25 Jul 2017 10:31:36 EDT

LAVAL, QUÉBEC--(Marketwired - 25 juillet 2017) - Neptune Technologies & Bioressources inc. (NASDAQ:NEPT)(TSX:NEPT) (« Neptune » ou « la Société »), annonce qu'elle tiendra une conférence téléphonique le 15 août 2017 à 8h00, heure normale de l'est, afin de commenter les résultats financiers du premier trimestre pour la période de trois mois se terminant le 30 juin 2017.




Neptune to Hold Conference Call to Discuss First Quarter Results for the Three Months Period Ended June 30, 2017

Tue, 25 Jul 2017 10:30:21 EDT

LAVAL, QUÉBEC--(Marketwired - July 25, 2017) - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ:NEPT)(TSX:NEPT), announces that it will be holding a conference call on August 15, 2017 at 8:00 AM (EST) to discuss its first quarter results for the three months period ended June 30, 2017.




Enablon Named an EH&S Software Leader with Strongest Product Capabilities and Momentum in the Industry

Tue, 25 Jul 2017 10:00:00 EDT

Independent Analyst Firm Sees Enablon Advancing Boundaries of Software Capabilities to Create New Standard in EH&S Management Technology




Utah Medical Products, Inc. Reports Financial Performance for Second Quarter 2017

Tue, 25 Jul 2017 09:00:00 EDT

SALT LAKE CITY, UT--(Marketwired - Jul 25, 2017) - In the second calendar quarter (2Q) and first half (1H) of 2017, Utah Medical Products, Inc. (NASDAQ: UTMD) achieved results which suggest the Company may significantly exceed previously announced goals for 2017.




FDA Allows Q-Cells(R) for First-In-Human Transverse Myelitis Trial

Tue, 25 Jul 2017 08:00:00 EDT

Phase 1/2a Trial Will Set the Stage for Applications in Multiple Sclerosis, Stroke and Spinal Cord Injury




AntriaBio Announces First Patient Dosed in Phase 1 Clinical Study of AB101

Tue, 25 Jul 2017 08:00:00 EDT

LOUISVILLE, CO--(Marketwired - July 25, 2017) - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with diabetes and metabolic diseases, announced today the dosing of the first patient in a Phase 1 first-in-human clinical trial of its lead product candidate, AB101.




Livewire Ergogenics, Inc. Announces Strategic Development Agreements and Appointments to Advisory Board

Tue, 25 Jul 2017 08:00:00 EDT

ANAHEIM, CA--(Marketwired - Jul 25, 2017) - LiveWire Ergogenics, Inc. (OTC PINK: LVVV), a company focused on research partnerships, product development and commercialization of cannabinoid-based products, today announced it has entered into development agreements with seasoned horticulturists Kyle McKay and Jason Olson. The company also announced their appointments to the newly formed "7xPure" Advisory and Compliance Board.




Endexx to Showcase Phyto-Bites at the 4th Annual SuperZoo Show 2017 in Las Vegas

Tue, 25 Jul 2017 08:00:00 EDT

CAVE CREEK, AZ--(Marketwired - Jul 25, 2017) - Endexx Corporation (OTC PINK: EDXC), a provider of innovative phyto-nutrient-based food and nutritional products, announced today it will be attending the SuperZoo Show held on July 25-27, 2017 at the Mandalay Bay Convention Center in Las Vegas.




Moleculin's New Drug for the Treatment of Glioblastoma Nears Clinical Trials at MD Anderson Cancer Center

Tue, 25 Jul 2017 07:30:00 EDT

HOUSTON, TX--(Marketwired - July 25, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has agreed to provide support to help accelerate the start of a physician-sponsored Investigational New Drug (IND) application to study the Company's drug candidate WP1066 for the treatment of adult glioblastoma (brain tumors).




Innovation canadienne : la société Hydropothecary lance le premier vaporisateur buccal de cannabis médical au Canada

Tue, 25 Jul 2017 07:00:00 EDT

GATINEAU, QC--(Marketwired - 25 juillet 2017) - La société Hydropothecary (TSX CROISSANCE: THCX) a annoncé aujourd'hui le lancement imminent d'Elixir No. 1, le seul vaporisateur légal de marijuana à utilisation sublinguale (sous la langue) au Canada.




Canadian Innovation: Hydropothecary Corporation set to release Canada's first-ever medical cannabis mouth spray

Tue, 25 Jul 2017 07:00:00 EDT

GATINEAU, QC--(Marketwired - July 25, 2017) - The Hydropothecary Corporation (TSX VENTURE: THCX) today announced it will soon launch Elixir No. 1 Canada's only legal medical marijuana sublingual (under tongue) mist.




MCIG Inc. Aggressively Seeks Acquisition of Medical and Recreational Marijuana License

Tue, 25 Jul 2017 07:00:00 EDT

HENDERSON, NV--(Marketwired - Jul 25, 2017) - mCig, Inc. (OTCQB: MCIG), a diversified company servicing the legal cannabis markets with innovative products, technologies, and services. mCig, Inc. is in a process of implementing a strategic plan that will help the company to accelerate its growth by expanding its reach in the cannabis market.




Top Pharma Companies Nurture Relationships with Payers Before, During and After Launch to Ensure and Retain Market Access

Mon, 24 Jul 2017 18:54:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwired - July 24, 2017) - Payer relationship management accounts for an average of 26% of surveyed global pharmaceutical and medical device companies' total market access budget, according to a recent study by business intelligence provider Cutting Edge Information.




REMSleep Holdings Inc. Announces the DeltaWave and its Patent Application -- A New Revolutionary CPAP Nasal Interface Device Designed to Improve Treatment for Sleep Apnea Patients

Mon, 24 Jul 2017 12:21:24 EDT

DES MOINES, IA--(Marketwired - Jul 24, 2017) - REMSleep Holdings, Inc. (OTC PINK: RMSL) (OTC PINK: RMSLD) www.remsleeptech.com is pleased to announce that it has filed a non-provisional patent with the US Patent and Trademark Office (Patent number 15/595,990 filed on March 16, 2017). The patent is titled "New Generation Sleep Apnea Device" and will ultimately be marketed under the product name "DeltaWave."




Dewmar International BMC, Inc. (DEWM) Files Paperwork with the United States Patent and Trademark Office to Secure Intellectual Property Related to Cannabinoids and Parkinson's Disease

Mon, 24 Jul 2017 11:49:29 EDT

New provisional patent will advance Dewmar's intellectual property assets related to Cannabinoids and is a follow up to last week's USPTO filing for lung cancer




The Alliance for Regenerative Medicine Announces Second Reimbursement and Market Access-Focused White Paper in Three-Part Series Published in In Vivo

Mon, 24 Jul 2017 10:35:59 EDT

WASHINGTON, DC--(Marketwired - Jul 24, 2017) - The Alliance for Regenerative Medicine (ARM) today announced the publication of its reimbursement and market-access focused white paper, "New Payment and Financing Models for Curative Regenerative Medicines," available online today in In Vivo.




SpeeDx Eyes Clear Path toward Marketing Antibiotic Resistance and Detection Tests in US Market

Mon, 24 Jul 2017 09:35:25 EDT

On-track for De Novo submission after successful meeting with the FDA




GeoVax Joins with Scripps Research Institute and Institute of Human Virology at University of Maryland School of Medicine to Develop Lassa Fever Vaccine

Mon, 24 Jul 2017 09:00:00 EDT

ATLANTA, GA--(Marketwired - Jul 24, 2017) -  GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with The Scripps Research Institute (TSRI) in La Jolla, CA, and the Institute of Human Virology (IHV) at the University of Maryland Medical School in Baltimore, MD, for advanced development of a preventive vaccine against Lassa hemorrhagic fever virus (LASV).




Exclusive CFN Media Interview with SolisTek (SLTK) CEO Dennis Forchic

Mon, 24 Jul 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Jul 24, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an exclusive interview with SolisTek (OTCQB: SLTK) CEO Dennis Forchic. SolisTek is an innovator in cannabis lighting solutions and has been offering unique technology designed specifically for marijuana cultivation for several years. This public company's catalogue includes digital lamps, ignition control with their proprietary SenseSmart technology, digital ballasts, and everything in between. CFN sat down with Mr. Forchic at the Spring MJ Biz Con in Washington, D.C. to learn more about the company and its unique properties.




AXIM Biotech: Cannabinoid Potential Worth the Complexity -- SECFilings.com

Mon, 24 Jul 2017 09:00:00 EDT

REDONDO BEACH, CA--(Marketwired - Jul 24, 2017) -  SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering AXIM® Biotechnologies Inc. (OTCQB: AXIM) and its approach to developing cannabinoid-based therapeutics. Medical marijuana legalization may be sweeping the nation, but the term is a bit of a misnomer when it comes to actual medical evidence. After all, medical cannabis hasn't been registered as a medicine in any country and only a handful of cannabinoid medicines have reached the market. The upshot is that many companies are working on developing cannabinoid-based therapeutics that appear very promising in early clinical trials.




Easton Pharmaceuticals Provides Shareholder Update On Acquisitions, Its Recent MMJ Initiative And Progress On Its Woman's Diagnostics and Treatment Segment

Mon, 24 Jul 2017 08:42:30 EDT

TORONTO, ON--(Marketwired - Jul 24, 2017) -  Easton Pharmaceuticals Inc. (OTC PINK: EAPH) provides shareholder update on new and existing acquisitions including its medical marijuana venture and progress on its woman's diagnostics and treatment segment products.




Cancer Immunotherapy Company Vaxil Appoints Dr. Terry Plasse as Chief Medical Officer

Mon, 24 Jul 2017 08:30:00 EDT

TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - July 24, 2017) - VAXIL BIO LTD. (TSX VENTURE: VXL), an Israeli-Canadian biotech developing innovative immunotherapy treatments for cancer, is pleased to announce the appointment of Dr. Terry Plasse as its Chief Medical Officer, responsible for the Company's clinical program surrounding its drug candidate, ImMucinT. Dr. Plasse brings 30 years of clinical development experience, including advancing products from IND through to commercially marketed treatments for several big-pharma companies.




BriaCell Expands Targeted Pipeline via Acquisition of Sapientia Pharmaceuticals

Mon, 24 Jul 2017 08:30:00 EDT

BERKELEY, CA and VANCOUVER, BC--(Marketwired - July 24, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce that it has entered into a definitive share exchange agreement (the "Share Exchange Agreement") with its wholly-owned subsidiary, BriaCell Therapeutics Corp. ("BriaCell USA"), a Delaware corporation, Sapientia Pharmaceuticals, Inc. ("Sapientia") and all the shareholders of Sapientia (the "Sapientia Shareholders"). Sapientia, a biotechnology company based in Havertown, PA, that is developing novel targeted therapeutics for multiple indications including several cancers and fibrotic diseases.




Rennova Health Announces the Opening of Big South Fork Medical Center Is on Track for August 8 Following CMS Regional Office Licensure Approval

Mon, 24 Jul 2017 08:30:00 EDT

WEST PALM BEACH, FL--(Marketwired - July 24, 2017) - Rennova Health, Inc. (NASDAQ: RNVA), (NASDAQ: RNVAZ) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announces the Life Safety and Licensure Survey conducted by the Tennessee Department of Health East Regional Office has concluded its inspection of Rennova's subsidiary Big South Fork Medical Center (legal name: Scott Community Hospital, Inc.), thereby approving the opening of Big South Fork Medical Center as planned for August 8, 2017.




Tetra Bio-Pharma Accelerates Growth Strategy with Appointment of Bernard Fortier as CEO

Mon, 24 Jul 2017 08:30:00 EDT

OTTAWA, ONTARIO--(Marketwired - July 24, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) today announced that it has strengthened its management team with the appointment of Bernard Fortier to the position of Chief Executive Officer, effective today, July 24, 2017. Mr. Andre Rancourt, previous interim CEO will take the position as Chairman of the Board of Directors. Mr. Andre Audet will step down as Chairman of the Board of Directors but will continue to serve as a Board member.




ORYZON presents final data on the Phase I trial with ORY-2001 at the Alzheimer's Association International Conference (AAIC-2017)

Mon, 24 Jul 2017 08:00:00 EDT

BARCELONA, SPAIN and CAMBRIDGE, MA--(Marketwired - July 24, 2017) -

  • Excellent safety data profile on 106 healthy volunteers
  • The molecule is brain penetrant
  • Data allows establishment of a safe administration scheme for long term efficacy studies



Amazonas Florestal Ltd. Announced Today That The Company's Wholly Owned Subsidiary, Amazon Hemp, will not be implementing a reverse stock split during 2017, and Further Announces Update on Hemp Plantations in Colorado

Mon, 24 Jul 2017 08:00:00 EDT

MIAMI, FL--(Marketwired - Jul 24, 2017) - Amazonas Florestal, Ltd. ("Amazonas Florestal" or the "company") (OTC PINK: AZFL), a premier provider and innovator of natural resources products, certification and sales of carbon credits, sustainable forest management resources and related services, as well as a pioneer to the development and enhancement of the evolving and legal Industrial CBD Hemp business, announced that AZFL will NOT be implementing a reverse stock split during 2017.




ProBility Media Corp. Further Expands International Educational and Training Product Offerings with Purchase of Cranbury International

Mon, 24 Jul 2017 07:57:46 EDT

HOUSTON, TX--(Marketwired - Jul 24, 2017) -  ProBility Media Corp. (OTCQB: PBYA), an EdTech company building the first full-service training and career advancement brand for the skilled trades, today announced that it has signed a binding letter of intent to purchase Cranbury International, an exporter of educational and reference materials, located in Montpelier, Vermont. The acquisition significantly expands ProBility's educational and training product offerings in South and Central America and the Caribbean. The closing is expected within 30 days.




Liberty Health Sciences Inc. Names Industry Veteran George Scorsis CEO and Director

Mon, 24 Jul 2017 07:00:00 EDT

TORONTO, ONTARIO--(Marketwired - July 24, 2017) - Liberty Health Sciences Inc. ("Liberty") has named seasoned executive George Scorsis as Chief Executive Officer and Director, effective immediately. Scorsis comes to Liberty with over 15 years' experience as a leader in highly regulated industries experiencing rapid growth, including alcohol, energy drinks and, most recently, medical cannabis.




Genetic Technologies Receives Nasdaq Deficiency Notice

Fri, 21 Jul 2017 21:57:53 EDT

MELBOURNE, AUSTRALIA--(Marketwired - Jul 21, 2017) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), today announced that on 20 July 2017, it received a notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market, notifying the Company that its closing bid price has been below the minimum $US1.00 per share requirement for a period of 30 consecutive business days and that the Company has not met the minimum bid price requirement of $US1.00 per share for continued inclusion under Nasdaq Marketplace Listing Rules (the "Rules").




Lakeside Announces 2017 Annual and Special Meeting Results

Fri, 21 Jul 2017 10:22:20 EDT

TORONTO, ONTARIO--(Marketwired - July 21, 2017) - Lakeside Minerals Inc., now Lineage Grow Company Ltd. (the "Company" or "Lineage") wishes to announce that at the July 19th, 2017 Annual and Special Meeting ("AGM") in Toronto, shareholders voted in favour of all items of business.




eWellness Signs LOI For Comprehensive PT Services with US Health Center and another US Healthcare Payer Group

Fri, 21 Jul 2017 09:00:00 EDT

CULVER CITY, CA--(Marketwired - Jul 21, 2017) - eWellness Healthcare Corporation -- (OTCQB: EWLL) -- a provider of the state of the art PHZIO Platform for the physical therapy and telehealth markets, announced today that it has signed a Letter of Intent Agreement between US Health Center, Inc. ("USHC") and an undisclosed US healthcare provider. Between both USHC and the undisclosed US healthcare payer group they anticipate having approximately 100,000 healthcare insured customers by the end of 2017. The Parties to this LOI have agreed to use their best efforts to conclude Definitive Agreements between the Parties over the next 90 days. According to eWellness, these new agreements (if executed) are anticipated to generate initially up to $4.2 million in annual reoccurring gross revenue for the Company. This level of sales is anticipated to allow the Company to gain cash flow positive operations during the latter part of 2017.




ECPO Files Issuers Company Related Action Notification with the Financial Industry Regulatory Authority requesting Name and Symbol Change

Thu, 20 Jul 2017 13:19:52 EDT

The Company Also Updated Progress on the Validation Process for its ITV-1 Patented HIV/AIDS Treatment